NOSIS™
Combined with AI, our proprietary biobank is the secret to how we find patterns that were previously invisible, making precision medicine for acute care possible.
A Biobank Built for Acute Illness
Prenosis has created the world’s largest immune biobank for acute illness. Today, NOSIS holds more than 140,000 samples from over 35,000 patients – roughly 20 times larger than any similar initiative in existence.
We collect data from the patient chart, including vitals, labs, outcomes, physician notes, demographics, comorbidities. Then we go further in our own BSL2 lab in Chicago, measuring roughly 50 novel biomarkers known to correlate with immune response.
The result? A view of each patient’s biology that doesn’t exist anywhere else.
Real-Time Data Generation. Exponential Value.
Every clinical trial we run adds new samples, new outcomes, and new signals to NOSIS, rapidly and exponentially increasing the value of our proprietary databank.
Large-scale observational data from patients treated under standard of care
Interventional randomized controlled trials that test novel therapies against placebo
Adaptive, real-time interventional trials, where the patient population shifts as we learn
Fueling the Future of Acute Care
From Biobank to Product Pipeline
NOSIS is the foundation for every product we build. Each new biomarker, each new trial, and each new patient encounter sharpens the models behind our existing products and expands what we can build next.